With the US dollar falling down a precipice, spare a thought for non-US investors invested in US stocks and bonds.

The graph below shows the performance of US 10-year Treasury Notes since the beginning of March in both US dollar terms (red line) and euro terms (blue line). Whereas US investors are showing a poor return of -2.8% for the period, European investors are completely under water to the tune of -17.5%. For the year to date the figures are -4.8% (US dollar) and -10.5% (euro). (Although I am using the euro in this example, the same logic applies to most other non-US dollar currencies.)

Source: StockCharts.com

The next graph illustrates the same principle for equities by comparing the performance of S&P 500 Index in US dollar terms

...

 

Deutsche Boerse and SIX Swiss Exchange have announced that they are buying out Dow Jones’ one-third stake in Stoxx for a consideration of 206.1 million euros, or $306 million.

Stoxx was set up as a joint venture between Deutsche Boerse, Dow Jones and SIX Swiss Exchange in 1998 in anticipation of the introduction of the euro and the creation of the eurozone. Stoxx is Europe's leading index provider in the ETF market and Europe's No. 1 (world No. 2) provider in the derivatives market, according to the company’s Web site. A number of U.S.-listed ETFs are tied to the company’s indexes as well.

Following the transaction’s completion, which is due to take place early next year, Deutsche Boerse will have a controlling stake in Stoxx of 50 percent plus one share and will fully consolidate it for accounting purposes.

In addition, SIX and Deutsche Boerse will set up a new entity

...

Save the World Air, Inc. (STWA) is a pioneer in the clean technology industry focused on energy efficiency and air quality issues. The company’s patented and patent pending technologies, including the innovative ELEKTRA under development with Temple University, provide a highly affordable and effective means of meeting the world’s increasing emission quality standards, boosting fuel efficiency and improving vehicle performance.

The Company continues to actively develop and finalize variants of the ELEKTRA and ZEFS (Zero Emissions Fuel Systems, ECO ChargR, and MagChargR) devices for use on carbureted, throttle body and multi-port fuel injection and diesel engine systems. In certified laboratory testing, STWA’s technologies have reduced air pollution in combustion engines by as much as 56% below Euro 3 standards (reducing greenhouse gases like NOX by as much as 65%), improved overall power by as much as 19%, and enhanced fuel efficiency.

STWA’s operational strategy is predicated on the further research and development,

...

It felt as if negotiations would go on for an eternity, with months of stalling: search this site for 'Opel bid' and the stories of stops and starts come thick and fast.  Now, just as it seemed that the deal was finally coming to a close, comes the spectacular announcement that GM will not in fact sell off its loss-making European unit Opel to the consortium of Canadian part-maker Magna and Russia's Sberbank, preferring to restructure it itself as the economic climate warms.  German Chancellor Angela Merkel, who had pledged €4.5bn in loans may well be fuming and apparently Prime Minister Putin has chimed in with his consternation over the abortive deal, which had promised ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday November 3, 2009

DrStockPick.com Stock Report!

**************************************************************

Power3 Medical Products, Inc. (OTCBB: PWRM), a leader in neurodegenerative disease and cancer biomarkers and diagnostic tests, announces further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf, will deliver an invited Keynote address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership

...

Whoever would have thought that some people once called economics the most dismal of sciences? Certainly, as the current crisis goes on and on, those of us who consider ourselves to be economists scarcely are able to find the time to squeeze in a dull moment, even here and there. But even at a broader level, interest in that most dismal of dismal topics - the theory and practice of central banking - seems now to fire up levels of enthusiasm here in Spain that make even the appetising prospect of a forthcoming Real Madrid-Barça football match pale in intensity. Even if it is the case, I have to admit, that the everyday Johnny (or Jill) come lately sitting in the bar still - truth be told - prefers the sports columns of the daily newspapers, or the lacivious details of the latest romantic adventure of one of the rich ...

This post provides links to a number of thought-provoking articles I have read over the past few days that you may also find of interest.

• Evans-Pritchard (Telegraph): German “wise men” fear credit crunch in 2010, October 15, 2009. Germany’s leading institutes have warned that the pace of economic recovery is “unsustainable” and that the country’s banks may face a fresh crisis over the next year as bad debts surface in earnest.

• Lasse Heje Pedersen (NYU Stern School of Business): When everyone runs for the exit, August 2009. The dangers of shouting “fire” in a crowded theater are well understood, but the dangers of rushing to the exit in the financial markets are more complex. Yet, the two events share several features …

• Anthony Bolton (Financial Times): Are developed or emerging markets the future of investing? October 16,

...

Early Wednesday afternoon, Merck announced that they have made a decision of research collaboration with Galapagos NV. The news about the research collaboration had positive responses from analysts and the shares of Merck went up shortly after the announcement was made. Building on the deal struck at the very beginning of the year, Merck has boosted its commitment on milestones for new atherosclerosis therapies for more than 400 million Euros. Galapagos NV was founded ten years ago as a joint venture between Crucell and Tibotec. The company has always adopted hybrid business model and have come up quickly raising funds through private placements and public offerings.

As per the strategic alliance between Merck and Galapagos for the development of new therapies for atherosclerosis, Galapagos VN will be responsible for the discovery

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Friday October 16, 2009, are:

**************************************************************

HSC, Harsco Corp.

HSC is a diversified industrial services company serving global industries that are fundamental to worldwide economic growth, including infrastructure, metals, railways and energy.

HSC is recognized as one of the Fortune 1000 leading companies in America and has been named five times to the Platinum 400 list of the best big companies by Forbes magazine.

HSC signed a new, multi-million dollar supply contract which expands its business with a major asphalt shingle manufacturer in the United States.

**************************************************************

ACAS, American Capital, Ltd.

ACAS, both directly and through its global asset management business,

...

Nokia Corp. (NOK) today declared financial results for the third quarter of fiscal 2009. Total revenue of Euro 9.8 billion was a decrease of 19.8% year-over-year as well as down 1% sequentially. The significant decline in year-over-year revenue is the result of the global economic recession and an extremely challenging market environment for the company’s Mobile Devices and Services segment as well as the telecom infrastructure development segment of Nokia Siemens Network. Net loss in the third quarter was Euro 559 million or a loss of Euro 15 per share, compared to a net income of Euro 1,087 million (an income of Euro 29 per share) in the prior-year quarter. Nokia incurred a massive loss in the reported quarter due to a whopping Euro 1,167 million of non-cash impairment charge. Out of this, Euro 908 million was expensed as the goodwill impairment charges for the Nokia Siemens ...